| pSLE |  | aSLE |  | ||
---|---|---|---|---|---|---|
 | OPNlo | OPNhi | P-value | OPNlo | OPNhi | P-value |
Current prednisone dosage, mg/day, median (range) | 10 (0, 60) | 30 (0, 40) | 0.6 | 5 (0, 5) | 12.5 (0, 60) | 0.1 |
High cumulative prednisone dose, patients, number (%) | 2 (13) | 8 (73) | 0.01 | 1 (25) | 3 (27) | 0.3 |
Current immunosuppressive use, patients, number (%) | 7 (44) | 7 (64) | 0.6 | 2 (25) | 5 (46) | 0.6 |
Renal involvement, patients, number (%) | 8 (50) | 8 (73) | 0.4 | 0 (0) | 4 (36) | 0.5 |
Disease duration, years | 2.3 ± 2.7 | 4.5 ± 3.5 | 0.2 | 8.5 ± 12.3 | 11.8 ± 7.6 | 0.7 |
SDI, median (range) | 0 (0, 3) | 2 (0, 5) | 0.01 | 0 (0, 2) | 0 (0, 2) | 0.9 |
SLEDAI, median (range) | 2 (0, 8) | 2 (0,16) | 0.3 | 2 (0, 8) | 4 (0, 8) | 0.6 |
ESR | 18 ± 7 | 54 ± 28 | 0.01 | 8 ± 6 | 45 ± 35 | 0.1 |
C3 | 100 ± 32 | 95 ± 40 | 0.7 | 115 ± 15 | 89 ± 24 | 0.9 |
C4 | 15 ± 5 |  | 0.7 | 22 ± 3.3 | 19.2 ± 5.5 | 0.3 |
αdsDNA, % patients negative/% patients positive | 46/8 | 40/40 | < 0.0001 | 100/0 | 43/29 | < 0.0001 |
αRBP, % patients positive | 25 | 45 | 0.003 | 20 | 43 | 0.0005 |